Drug Trial News

RSS

Advaxis receives DSMB approval to complete dosing in first leg of ADXS11-001 cervical dysplasia clinical trial

The science team from Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, met with the Data Safety Monitoring Board (DSMB), an independent group of medical experts, yesterday and received approval to dose all remaining patients in the initial forty (40) patient leg of the 120-patient, cervical dysplasia clinical trial being conducted in the United States.

14 Jan 2011

Merck announces changes in vorapaxar clinical studies

Merck today provided the following statement on the changes to the clinical studies for vorapaxar, one of the Company's investigational cardiovascular medicines, following an announcement from the two academic centers leading the studies of vorapaxar.

14 Jan 2011

Adjunctive lacosamide reduces seizures and improves responder rates

Comprehensive analyses of pooled data from three randomized, double-blind, placebo-controlled Phase II/III trials showing the efficacy and tolerability of Vimpat® (lacosamide) C-V for patients with partial-onset seizures, regardless of the type of concomitant AED used, have been published in the drug evaluation journal, CNS Drugs.

13 Jan 2011

BioCryst reports positive results from peramivir Phase 3 study in influenza

BioCryst Pharmaceuticals, Inc. today announced top-line results from one of its two Phase 3 studies of intravenous (i.v.) peramivir for the treatment of patients hospitalized with influenza, and provided an update regarding its peramivir program.

13 Jan 2011

BP-lowering medications provide long-term benefit of reducing death risk from cardiovascular disease

In a study published in December 2010, in Hypertension, a journal of the American Heart Association, investigators have shown that early treatment with blood pressure-lowering medications provides a long-term benefit of reducing the risk of death from cardiovascular disease.

13 Jan 2011

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FibroGen, Inc. today announced initiation of an open-label phase 2 study to evaluate the safety, tolerability, and efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), in individuals with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fatal lung disease for which there are no FDA-approved therapies.

13 Jan 2011

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a joint collaboration with Synta Pharmaceuticals for the clinical development of ganetespib (formerly STA-9090) in patients with multiple myeloma.

13 Jan 2011

Researchers launch estrogen therapy trial to study depression, cardiovascular illness in women

Researchers at the University of North Carolina at Chapel Hill have launched a new clinical trial to determine if estrogen replacement therapy may help prevent depression and cardiovascular illness in women between the ages of 45 and 55.

13 Jan 2011

TKM-PLK1 drug may offer hope for patients with advanced solid tumor cancers

A new investigational drug designed to stop cancer cells from reproducing may offer hope for patients with advanced solid tumor cancers. Clinical trials of TKM-PLK1 for qualified patients are now open at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

13 Jan 2011

Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer

MedImmune, the global biologics unit of AstraZeneca PLC and Micromet, today announced the initiation of a Phase 1 trial of MEDI-565 in patients with advanced gastrointestinal cancers. MEDI-565 is a BiTE antibody designed to direct a patient's T cells, the body's most potent killer cells, against cancer cells that express carcinoembryonic antigen.

13 Jan 2011

AstraZeneca, CANCER RESEARCH UK enter strategic alliance to conduct experimental cancer drug trials

CANCER RESEARCH UK's drug development office has signed a Strategic Combinations Alliance with AstraZeneca to take combinations of experimental cancer drugs into early phase clinical trials.

12 Jan 2011

GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease

GlaxoSmithKline and ChemoCentryx, announced today that the first patient with Crohn's disease has initiated treatment in the initial pivotal induction study comparing Traficet-EN, now designated GSK1605786 ('786), to placebo.

12 Jan 2011

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.

12 Jan 2011

Scientists find way to prevent early stage pancreatic cancer in research models

Cancer researchers at The Peggy and Charles Stephenson Oklahoma Cancer Center have found a way to stop early stage pancreatic cancer in research models - a result that has far-reaching implications in chemoprevention for high-risk patients.

12 Jan 2011

Epigenetic therapy holds promise for cancer management

Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research.

12 Jan 2011

UH, Case Western University commence clinical trial for bipolar disorder

The Mood Disorders Program at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, along with the Bipolar Trials Network, is launching Bipolar CHOICE.

12 Jan 2011

Rib-X raises $20M to support development of broad spectrum antibiotics pipeline

Rib-X Pharmaceuticals, Inc. today announced that the Company has raised $20 million to support ongoing development of the Company's industry-leading broad spectrum antibiotics pipeline, including late-stage clinical development of delafloxacin, which is expected to enter a Phase 2b study in early 2011.

11 Jan 2011

FemmePharma completes FP 1097 Phase II clinical trial in women with OAB

FemmePharma Global Healthcare, a privately held women's health company dedicated to improving the quality of life for women, today announces completion of its Phase II clinical dose ranging/safety trial with FP 1097 in women suffering from urinary incontinence or overactive bladder.

11 Jan 2011

SciClone initiates phase 2b study of SCV-O7 for oral mucositis

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of the first patient in the company's phase 2b clinical trial of SCV-07 for the prevention of oral mucositis (OM) -- a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and neck cancer.

11 Jan 2011

ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis

ALLOZYNE, Inc. announced today, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatment of relapsing remitting multiple sclerosis. The objectives of the Phase IA trial were to assess safety and tolerability profile in addition to defining its pharmacological properties.

11 Jan 2011

Drug Trial News

Advaxis receives DSMB approval to complete dosing in first leg of ADXS11-001 cervical dysplasia clinical trial

Merck announces changes in vorapaxar clinical studies

Adjunctive lacosamide reduces seizures and improves responder rates

BioCryst reports positive results from peramivir Phase 3 study in influenza

BP-lowering medications provide long-term benefit of reducing death risk from cardiovascular disease

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

Researchers launch estrogen therapy trial to study depression, cardiovascular illness in women

TKM-PLK1 drug may offer hope for patients with advanced solid tumor cancers

Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer

AstraZeneca, CANCER RESEARCH UK enter strategic alliance to conduct experimental cancer drug trials

GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Scientists find way to prevent early stage pancreatic cancer in research models

Epigenetic therapy holds promise for cancer management

UH, Case Western University commence clinical trial for bipolar disorder

Rib-X raises $20M to support development of broad spectrum antibiotics pipeline

FemmePharma completes FP 1097 Phase II clinical trial in women with OAB

SciClone initiates phase 2b study of SCV-O7 for oral mucositis

ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News